KR20110025178A - Ｐｍ00104 및 다른 항종양제를 이용한 복합 치료법 - Google Patents

Ｐｍ00104 및 다른 항종양제를 이용한 복합 치료법 Download PDF

Info

Publication number
KR20110025178A
KR20110025178A KR1020107028378A KR20107028378A KR20110025178A KR 20110025178 A KR20110025178 A KR 20110025178A KR 1020107028378 A KR1020107028378 A KR 1020107028378A KR 20107028378 A KR20107028378 A KR 20107028378A KR 20110025178 A KR20110025178 A KR 20110025178A
Authority
KR
South Korea
Prior art keywords
combination
day
cancer
tumor
anticancer drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107028378A
Other languages
English (en)
Korean (ko)
Inventor
도린 르파쥐
마린 파블로 마누엘 아빌레스
나바로 마리아 호세 길렌
Original Assignee
파르마 마르 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파르마 마르 에스.에이. filed Critical 파르마 마르 에스.에이.
Publication of KR20110025178A publication Critical patent/KR20110025178A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020107028378A 2008-05-16 2009-05-18 Ｐｍ00104 및 다른 항종양제를 이용한 복합 치료법 Withdrawn KR20110025178A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5372608P 2008-05-16 2008-05-16
US61/053,726 2008-05-16

Publications (1)

Publication Number Publication Date
KR20110025178A true KR20110025178A (ko) 2011-03-09

Family

ID=41136781

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107028378A Withdrawn KR20110025178A (ko) 2008-05-16 2009-05-18 Ｐｍ00104 및 다른 항종양제를 이용한 복합 치료법

Country Status (12)

Country Link
US (1) US20110070232A1 (enExample)
EP (1) EP2307003A2 (enExample)
JP (1) JP2011520921A (enExample)
KR (1) KR20110025178A (enExample)
CN (1) CN102099025A (enExample)
AU (1) AU2009246130A1 (enExample)
CA (1) CA2724325A1 (enExample)
IL (1) IL209361A0 (enExample)
MX (1) MX2010012501A (enExample)
NZ (1) NZ589269A (enExample)
RU (1) RU2010151602A (enExample)
WO (1) WO2009140675A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
HUE042801T2 (hu) 2010-11-12 2019-07-29 Pharma Mar Sa Kombinációs terápia mitózisgátlóval
US9192609B2 (en) * 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CN120661674A (zh) * 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
KR102260846B1 (ko) * 2018-07-09 2021-06-07 국립암센터 고시폴, 펜포르민 및 항암제를 포함하는 암 예방 또는 치료용 약학적 조성물
PH12022551216A1 (en) 2019-11-21 2023-07-17 Pharma Mar Sa Methods of treating small cell lung cancer with lurbinectedin formulations
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1854597A (en) * 1996-01-31 1997-08-22 Board Of Regents, The University Of Texas System Sensitization of HER2/neu over-expressing cancer cells to chemotherapeutic dr ugs
CA2294031E (en) * 1997-07-29 2012-04-03 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
AU770309B2 (en) * 1998-06-05 2004-02-19 Regent Court Technologies Monoamine oxidase (MAO) inhibitors and uses thereof
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
EP1254140A4 (en) * 2000-01-19 2003-03-12 Univ Columbia SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USES AND SYNTHESIS
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0229793D0 (en) * 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
EP2301533A1 (en) * 2004-07-09 2011-03-30 University of Pittsburgh Wortmannin Analogs and Method of Using Same
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2006311877A1 (en) * 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
US20070117815A1 (en) * 2005-11-04 2007-05-24 James Pluda Method of treating cancers with SAHA and pemetrexed
EP2043653B1 (en) * 2006-06-21 2013-12-25 Eli Lilly And Company Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
RU2519750C2 (ru) * 2008-05-16 2014-06-20 Фарма Мар, С.А. Способы лечения множественной миеломы

Also Published As

Publication number Publication date
WO2009140675A2 (en) 2009-11-19
CN102099025A (zh) 2011-06-15
RU2010151602A (ru) 2012-06-27
WO2009140675A3 (en) 2010-04-01
US20110070232A1 (en) 2011-03-24
IL209361A0 (en) 2011-01-31
AU2009246130A1 (en) 2009-11-19
CA2724325A1 (en) 2009-11-19
NZ589269A (en) 2013-03-28
MX2010012501A (es) 2010-12-20
EP2307003A2 (en) 2011-04-13
JP2011520921A (ja) 2011-07-21

Similar Documents

Publication Publication Date Title
KR20110025178A (ko) Ｐｍ00104 및 다른 항종양제를 이용한 복합 치료법
RU2605335C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
JP5393159B2 (ja) 改善された抗腫瘍治療
US8927530B2 (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
RU2429838C2 (ru) Комбинированная химиотерапия
KR20060009371A (ko) 히스톤 데아세틸라제 저해 물질을 함유하는 의약 조성물
KR20100126479A (ko) 개선된 항종양 치료법들
EP1323423A1 (en) Combined preparations comprising anthracycline derivatives
US7622458B2 (en) Combination of ET-743 and a 5-fluorouracil pro-drug for cancer treatment
US20250339416A1 (en) Ezh1/2 dual inhibitor-containing pharmaceutical composition to be used as a combination drug
US20110009335A1 (en) Anticancer Treatments
KR20080048489A (ko) 신규 항암 병용제
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
KR20070086123A (ko) 하나 이상의 돌라스타틴 10 유도체를 포함하는 신규 약학조성물
HK1202421B (en) Combination therapy with an antitumor antibiotic
HK1202419B (en) Combination therapy with a mitotic inhibitor
HK1202423B (en) Combination therapy with a topoisomerase inhibitor
HK1177889A1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid